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Objective: Shared decision-making, including the elicitation of patient preferences regarding treatment 
decisions, is considered part of high-quality cancer care. However, patients may not be able to self-report 
due to illness, and therefore proxy reports may be used. We sought to determine the difference between 
proxy and patient reports about patient decisions and preferences among patients who received or were 
scheduled for chemotherapy using data from a large, population-based survey of patients with incident 
lung or colorectal cancer.  
Methods: Of 3,573 patients who received or were scheduled for chemotherapy, 3,108 self-reported and 
465 had proxies reporting on their behalf about preferred and actual decision roles regarding this 
treatment. Preferred and actual decision roles were assessed using the Control Preferences Scale, and 
categorized as shared, patient-controlled, or doctor-controlled. Multivariable logistic regression models 
were used to assess the association between patient and proxy responses and whether preferences were 
met. The models adjusted for sociodemographic and clinical variables and patient/proxy-reported health 
status.  
Results: Sixty-three percent of all respondents reported actual roles in decisions that matched their 
preferred roles (role attainment). Proxies and patients were similarly likely to report role attainment (65% 
vs 63%).  In adjusted analyses, proxies were more likely report role attainment (OR=1.27, 95%CI=1.02-
1.59), but this difference was smaller if health variables were excluded from the model (OR=1.14, 
95%CI=0.92-1.41). 
Conclusion: Most patients’ preferences for treatment participation were met. Surveys from proxies 
appear to yield small differences on the reports of attainment of preferred treatment decision-making roles 
in cancer care versus surveys from patients.  
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The Institute of Medicine defines high-quality cancer care as patient-centric, and specifies that such 
care includes good communication and shared decision making.1 Eliciting patient treatment preferences is 
emphasized as part of high-quality communication.1 Previous research has indicated that patient preferences 
for treatment engagement vary, but patients who attained their preferred roles were more satisfied with 
treatment decisions.2 Shared decision-making has been positively associated with perceived care quality,3 
while not attaining one’s preferred decision-making role is negatively associated with health-related quality 
of life.4       
Additionally, surveys assessing how patients experience care are frequent.5-7 This assessment can 
include an evaluation of shared decision-making; for example, the Consumer Assessment of Health Plans 
Survey (CAHPS) for Cancer Care includes supplemental items related to shared decision-making.8 
However, such experience surveys do not solely involve patients. If patients are unable to respond, proxies 
are asked to report on the patient’s behalf. The potential impact of proxy reporting in experience surveys 
has been evaluated previously.5, 9 However, information on how proxy reporting may affect estimates of 
shared decision-making is limited.  
Research suggests that proxy reports best approximate patient reports when the outcome of interest 
is observable.10 Evaluating treatment decision-making roles requires the assessment of both patient 
preferences and the actual role in decisions that patients experienced. Furthermore, proxies may project 
their own preferences on to the patient,11 although this finding is not consistent across studies.12 The 
evaluation of proxy-patient concordance using paired data has had mixed results. Concordance with current 
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preferences was moderate to good for patients with mild dementia and their spouses and caregivers,12, 13 but 
poorer regarding preferences for hypothetical scenarios involving future events.13 
Importantly, this previous research has primarily emphasized hypothetical or future treatment 
scenarios. In contrast, experience surveys focus on past or current treatment decisions. Thus, it is unclear 
how applicable the previous literature is to this context. Paired proxy-patient evaluations are important for 
assessing concordance, but the generalizability of such results to situations where patients are unable to 
self-report is unclear. It is important to understand the impact of proxy reporting in such situations.  
We therefore sought to understand if including proxy reports was associated with preferred decision 
roles and role attainment using a large, population-based survey of patients with newly-diagnosed cancer. 
We focused on treatment decisions relating to chemotherapy as it remains a mainstay of cancer treatment. 
Additionally, new payment models seeking to improve cancer care in the US such as the Oncology Care 
Model have focused on practices that administer chemotherapy.14   
METHODS 
Patients and Settings 
We used data from the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) 
study, a large, multi-regional, population-based study of patients with newly-diagnosed lung or colorectal 
cancer during 2003 to 2005 identified using rapid case ascertainment.15 Briefly, CanCORS participants 
were drawn from multiple US geographic regions and health systems in the US. Interviewers surveyed 
participants approximately three to six months after diagnosis using computer-assisted telephone 
interviews.15 Patients who were contacted but unable to respond due to illness or other factors nominated a 
proxy to complete the interview on their behalf. Patients or their proxies reported sociodemographic and 
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clinical information, symptoms, health-related quality of life, care experiences, and preferred and actual 
decision-making roles. American Joint Committee on Cancer stage was abstracted from medical records. 
If medical record data were not available, stage was obtained from cancer registries (for a small number of 
patients, only historical stage was available). Additional details about CanCORS recruitment,16 
representativeness,17 survey instruments18 and imputation methods19 have been reported elsewhere. The 
American Association for Public Opinion Research17 survey response rate was 51.0% and the cooperation 
rate (“the proportion of all cases interviewed of all eligible units ever contacted”)20(p.6) was 59.9%. The 
Dana-Farber Cancer Institute approved the CanCORS study (2002-P-000196), and approvals were obtained 
for CanCORS Primary Data Collection Research (PDCR) sites. The CanCORS study was approved by 
human subjects research committees (IRBs) at all participating institutions. Participants at 2 PDCR sites 
provided written informed consent. The other site IRBs waived this requirement; verbal informed consent 
was obtained at those sites in lieu of written consent. CanCORS was conducted in agreement with the 
Declaration of Helsinki. 
This analysis used the core (dataset version 1.18) and baseline survey (dataset version 1.12) 
datasets. Among the 6471 patients or proxies who completed the baseline survey, we focused on the 3573 
participants (465 proxies and 3108 patients) who reported receiving or being scheduled to receive 
chemotherapy and also provided information about their preferred decision-making roles and their decision-
making role with regard to chemotherapy. Only n=62 patients were not eligible to be included in the study 
population (Appendix 1). 
Instruments 
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Patient decision preferences and actual roles were measured using categories derived from the 
Control Preferences Scale.21 To assess preferences, patients were asked as to the role they would prefer to 
play in treatment decision-making. Following the question, a series of statements (Table 1) were provided 
and patients indicated their agreement with one of the statements. Patients were also asked about the role 
they played regarding the decision about chemotherapy and the same statements were provided, with 
“prefer to make the decision” changed to “made the decision.” Proxies were asked the same question and 
provided the same statements, but the question prompt referred to the role the patient preferred to 
play/played. Following previous studies,3, 22 we categorized these roles into three groups, defined as 
“patient-controlled,” “shared,” and “doctor-controlled” decisions (Table 1). We considered patients to have 
attained their preferred role if the preferred and actual roles were in the same category (e.g., both shared). 
As noted above, patient socio-demographic characteristics were collected as part of the CanCORS 
questionnaire, as was medical history (e.g. comorbid conditions).18 The health status questions in CanCORS 
were from the SF-12.18 For health status questions, patients were asked about how they felt, whereas proxies 
were asked how they thought the patient was feeling. 
Data Analyses 
The primary independent variable was the use of a proxy respondent. Using an indicator variable 
for proxy status is a common method in surveys that collect proxy-reported data.23 After reviewing the 
literature, including the CAHPS instruments,24, 25 we identified covariates to include in our adjustment 
models. These included patient age, race, whether the patient had Medicaid/low-income insurance and 
patient or proxy-reported patient co-morbidities, general health status, and mental health status 
(operationalized as how often the patient felt calm and peaceful); this covariate has been used in previous 
CAHPS analyses.26 We also adjusted for CanCORS study site, the language in which the survey was 
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administered (English, Spanish, and Chinese), cancer type (lung/colorectal), and cancer stage, defined as 
not advanced (stage I, II, III, local/regional), advanced (stage IV, distant), or unstaged.   
Statistical Methods 
Descriptive statistics were used to compare proxy and patient reports of preferred and actual roles. 
Multivariable logistic regression models were used to explore the conditional association of proxy 
respondent status with role attainment, adjusting for the covariates listed above. To examine the sensitivity 
of the estimates to the health status covariates, we also explored multivariable logistic regression models 
that accounted for all characteristics except patient- and proxy-reported patient general and mental health 
(because poor patient health may lead to proxy responses). We obtained adjusted probabilities of role 
attainment by respondent status, holding all other variables at their mean values. Finally, among proxies, 
we examined if their relationship with the patient affected reports of role attainment after adjusting for the 
aforementioned covariates using a multivariable logistic regression model. Analyses were conducted using 
SAS (v9.4) and Stata (v15.0). 
In our study population, approximately 4% of covariates were missing and were imputed using 
multiple imputation (MI). MI was implemented centrally with IVEware,19 resulting in m=5 imputed 
datasets. Analyses were conducted within each imputed dataset and then pooled using Rubin’s rules. The 
Hosmer-Lemeshow test was used to assess model fit. Because there is no current best practice for evaluating 
logistic regression models in multiply imputed datasets,27 we examined the Hosmer-Lemeshow test statistic 
in each imputed dataset.     
RESULTS 
Sample Characteristics 
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Among 3,573 patients who received or were going to receive chemotherapy, 465 (13%) had proxies 
respond to the survey. Of these 465 proxies, 259 (55.7%) were the patient’s spouse/partner and overall 440 
(95%) were a member of the patient’s family. Compared with patients who reported for themselves, those 
with proxies tended to be older (16% vs. 5% aged ≥80 years, Table 2) and to have advanced disease (39% 
vs 30%). Additionally, reports of health status differed: 20% of patients with proxies had “poor” proxy-
reported health compared with 6% of patients who self-reported.  
Treatment Preferences and Role Attainment 
Few proxies and patients reported a preference for doctor-controlled decision-making (8% and 6%, 
respectively) (Table 2). Proxies were more likely than patients to report patient preferences for patient-
controlled decisions (43% vs 36%), and less likely to report preferences for shared decisions (49% vs 58%). 
Overall, role attainment (defined as an actual decision role that matched the preferred role) was achieved 
for 63% of patients regardless of respondent type. Nearly two-thirds of proxies (65%) and patients (63%) 
were classified as having reported role attainment.  
Among patients preferring doctor-controlled decisions (Table 3), only 38% of proxies endorsed 
role attainment, compared with 48% of patients. Role attainment was reported for 69% of patients with 
proxies and 67% of patients preferring patient-controlled roles. For patients with preferences for shared 
decision-making, 65% of patients with proxies reported role attainment versus 62% of patients.  
Association of Respondent Type and Role Attainment After Adjustment 
In adjusted analyses (Table 4), there was a conditional association between proxy status and role 
attainment (OR 1.27, 95% CI 1.02-1.59); the adjusted probabilities of role attainment were 75% for proxy 
report and 70% for patient report (data not shown). If proxy- and patient-reported patient health status 
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covariates were excluded from the adjusted model, the association was smaller and no longer statistically 
significant (OR 1.14, 95% CI 0.92-1.41), and the adjusted probabilities for role attainment were 73% for 
proxies and 71% for patients (data not shown).  
Among proxies, the type of relationship with the patient was not significantly associated with 
reports of role attainment. Compared to spouses, children (OR 0.91, 95% CI 0.54-1.54) and other relatives 
(OR 0.89, 95% CI 0.41-1.93) were less likely to report role attainment, whereas other non-relatives (OR 
1.48, 95% CI 0.54-4.03) were more likely (data not shown). 
DISCUSSION 
Our evaluation of proxy respondent status for reported attainment of preferred decision-roles 
among patients receiving chemotherapy in a large, population-based cohort found generally similar rates 
of decision role attainment among patients whether decision roles were reported by patients themselves or 
proxies. In fully adjusted analyses, proxy reports were associated with statistically significant greater patient 
attainment of their preferred treatment decision roles, but this result was not statistically significant when 
proxy- and patient-reported health status were not included in the model. Furthermore, the proxy-patient 
relationship was not significantly associated with proxy reports of patient role attainment.   
Our findings of overall and by-respondent levels of role attainment are consistent with other 
studies;28 previous reviews of the cancer literature have reported mismatches between preferred and actual 
treatment roles.29 However, Colley et al’s recent work in patients receiving chemotherapy found higher 
rates of role attainment (88.7%).30 One possible explanation for this discrepancy may be the patient 
population. Previous reviews29 and studies30 have indicated that decisional preferences vary across cancer 
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types. Our study included patients with lung and colorectal cancer, while Colley et al’s study included 
patients with breast, gastrointestinal, gynecological and lung cancer. 
The highest levels of role mismatch in our study were seen among patients and proxies reporting 
patient preferences for doctor-controlled decisions, but this group comprised a small proportion of the 
population. Additionally, our study reports patient- and proxy-reported preferences collected at one time 
point. Role preferences can and do change over time,29 however they are often assessed at one time point. 
Future longitudinal research may be worthwhile.  
One possible explanation for the small discrepancy between patient and proxy reports in our study 
may be that although role preferences are not as observable as other outcomes, it may be easier for proxies 
to report on preferences and actual roles pertaining to recent treatment decisions. CanCORS participants 
enrolled within three to six months after diagnosis and thus proxies were asked to report on relatively recent 
events. Earlier studies of paired proxy-patient concordance relating to preferences frequently describe 
hypothetical scenarios, rather than past events. However, even with hypothetical scenarios, proxies tend to 
more accurately predict treatment preferences in scenarios relating to the patient’s current versus future 
health.31 This suggests that studies asking proxies to evaluate preferred and recent actual treatment decision 
roles may be asking for outcomes that are comparatively easier for proxies to report than other decision-
making outcomes frequently evaluated in the literature. 
Of possible concern is that despite our finding of association between proxy status and role 
attainment, this association appeared to be stronger in adjusted models, particularly if we included patient- 
or proxy-reported health status covariates as adjustment variables. In many health surveys, proxies report 
patient health status and these reports are used as covariates; health status is an important predictor of other 
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outcomes such as care experience.32 Because proxies tend to report on behalf of sicker patients, it is not 
clear if this reflects a true difference in experience or if it reflects proxy reporting bias. One possible 
explanation may be that proxies have greater involvement in the care of sicker patients as such care may be 
more complex. Additionally, it is unlikely that cancer stage alone may account for burden of disease and 
thus assessment of health status is important; however, the possibility of proxies inaccurately reporting 
health status must also be considered. Although health status is likely associated with proxy report, the 
association of health status and role attainment is less clear. Role attainment and quality of life were not 
associated in a study of patients with advanced lung cancer.33 In any case, studies collecting both health 
status and role preference variables should consider sensitivity analyses to examine the robustness of their 
results to proxy-reported patient health status covariates and examine possible reasons for discrepancies.   
Study Limitations 
The strengths of this study include the use of a large, population-based cohort of newly-diagnosed 
cancer patients with many covariates. Although several studies have evaluated proxy-patient concordance 
about patient preferences using hypothetical scenarios and vignettes, this is one of the first to evaluate proxy 
reports of actual and preferred patient decision-making roles relating to patient treatment. Additionally, to 
the best of our knowledge few studies have compared reports of actual and preferred decision roles in 
population-based cohorts.  
The study also has limitations. The Control Preference Scale may not fit well to all situations and 
in some contexts patients with cancer may struggle to perceive decisions as truly shared.34 However, this 
scale is widely used in a variety of settings,28, 35 including cancer,30, 36, 37 and thus our analysis provides 
practical insight. Second, the study is subject to nonresponse bias; however, our response rate of 51% 
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compares favorably with other general population-based surveys, such as the Behavioral Risk Factor 
Surveillance System.38 Additionally, although the question prompt for the actual decision role referred to 
chemotherapy specifically, the question about preferred decision roles did not; a chemotherapy-specific 
question prompt may have resulted in different answers. Because we do not have paired patient and proxy 
reports, we cannot be sure if our findings are because proxy respondents report differently than patients or 
because patients in our study for whom proxies reported had different decision experiences. A further 
limitation is that we restricted our analysis to the population of patients who received or were scheduled for 
chemotherapy and asked patients about decisions three to six months after diagnosis. Although this has the 
benefit of situating our study with current efforts such as the Oncology Care Model which focus on patients 
who receive chemotherapy, results may differ for patients who do not receive chemotherapy or who are 
surveyed before beginning chemotherapy. Finally, the CanCORS data were collected in 2003 – 2005, and 
substantial advances in cancer treatment have occurred since that time, although chemotherapy remains an 
important component of anti-cancer therapy. However, CanCORS is one of the few population-based 
studies assessing patient care experience and thus the results may be more informative than analyses from 
a more recent convenience sample. Additionally, this study has a methodological focus in which the age of 
the data is less of a concern, as it is unclear how newer therapies would affect proxy reporting.  
Clinical Implications 
Our findings have implications for population-based or survey-based assessment of SDM in 
medical oncology, which may occur as part of experience and quality assessment for oncology clinicians. 
Future work examining this issue in other cancer types or more recent data would be worthwhile, given 
therapeutic advances as well as complex decision-making, for example for hematologic cancers such as 
multiple myeloma39 and the acute presentation of acute myeloid leukemia.40 Acutely-ill patients (e.g., with 
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acute leukemia) or those undergoing stem cell therapy, necessitating inpatient hospitalization, may have a 
greater need for and use of proxies, and thus assessment of this issue in other patient populations is an 
important next step. 
Conclusions 
We found relatively small differences between patient and proxy reports of the attainment of 
preferred treatment decision-making roles in a population-based cohort of patients with lung or colorectal 
cancer. These data suggest that the use of proxies may have a small impact on reports of attainment of 
preferred treatment decision-making roles in these tumor groups. 
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Table 1. Categorization of roles (derived from the Control Preferences Scale) 
Category Statement 




To make the decision with little or 
no input from your doctor(s) 
To make the decision after 
considering your doctor’s opinion 





Your doctor to make the decision 
after considering your opinion 
Your doctor to make the decision 
with little or no input from you 
†Proxy version refers to “[the patient’s name]” rather than “you” 
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Table 2. Selected characteristics of study participants  















































































Patient feels calm/peaceful† 
None of the time 
A little of the time 
Some of the time 
Most of the time 
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Characteristic Overall(N=3573) Proxy(N=465) Patient(N=3108) 
CanCORS study site 
5 integrated delivery systems 
8 counties in Northern CA  
State of Alabama 
Los Angeles County 
State of Iowa 
23 counties in North Carolina 





















































































































†Self-reported if patient, proxy-reported if proxy  
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Table 3. Unadjusted analyses (observed, non-imputed data): Role attainment by preferred role 
Category Proxy(N=465) Patient(N=3108) Overall(N=3573) 
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Table 4. Association of proxy status with role attainment: Logistic regressions 
























Patient feels calm/peaceful† 
None of the time 
A little of the time 
Some of the time 
Most of the time 








†Mental health status measure; ‡All analyses, unless otherwise specified, include adjustment for patient general and 
mental health status, insurance status, survey language, cancer type and stage, CanCORS site, chemotherapy 
completion status, and patient co-morbidities 
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